Healthcare >> CEO Interviews >> November 15, 2010
Dr. Mark Corrigan has served as Zalicus' President and Chief Executive Officer since January 2010. Dr. Corrigan joined U.S.-based specialty pharmaceutical company Sepracor, Inc., in 2003 and served as its Executive Vice President, Research and Development, until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as Group Vice President of Global Clinical Research and Experimental Medicine. He has been a member of the board of directors and the audit committee of Cubist Pharmaceuticals, Inc., since 2008. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina School of Medicine, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and M.D. from the University of Virginia, and he subsequently received specialty training in psychiatry at Maine Medical Center and Cornell University. Profile
TWST: Let's begin with a brief history and background on Zalicus and perhaps an explanation of the recent name change from CombinatoRx?
Dr. Corrigan: Zalicus (ZLCS)represents two former companies,
